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Background: The control of airway inflammation is crucial for management of asthma.
Theophylline has been demonstrated to have an anti-inflammatory effect as a long-
term-medication for asthma in various studies. In the present study we attempted to
clarify if aminophylline, a theophylline derivative, could act as an anti-inflammatory
agent as well as a bronchodilator in the treatment for acute asthma exacerbations.
Methods: Patients are initially treated either with an intravenous infusion of
aminophylline or with inhalation of salbutamol. Pro-inflammatory mediators such as
eosinophil cationic protein (ECP), histamine, serotonin, thromboxane B2, leukotriene
C4 were measured before and one hour after the initial treatment. Clinical parameters
such as peak expiratory flow (PEF) and SpO2 were also checked during the studies.
Results: Significant improvements of PEF and SpO2 with both aminophylline and
salbutamol treatment were seen. Furthermore, significant decreases of ECP,
histamine, and serotonin were observed with aminophylline but not with salbutamol.
Conclusions: Suppressing the release of pro-inflammatory mediators may play a role, at
least in part, in the beneficial effects of aminophylline in the treatment of acute exacer-
bations in asthma. Additionally, this study indicated that treatment with aminophylline is
at least as beneficial as nebulized salbutamol in the restoration of lung function.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Bronchial asthma has been recognized as an
inflammatory disease in which various inflamma-Elsevier Ltd. All rights reserve
964 1211;
yo-u.ac.jp (K. Ohta).tory cells and pro-inflammatory mediators play a
pivotal role. In these aspects of bronchial asthma,
treatments with anti-inflammatory agents such as
corticosteroids for the control of airway inflamma-
tion combined with bronchodilators such as b2-
agonists and/or theophylline are recommended.
The significance of monitoring inflammatory pro-
cesses as well as measuring respiratory functiond.
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ment of this disease has also been recognized. To
monitor the inflammatory processes in asthma,
various pro-inflammatory cytokines and chemical
mediators have been measured and some of those
measurements were demonstrated to be useful in
evaluating the efficacy of treatments in the control
of allergic inflammations in asthma.1,2 Importantly,
it has been proved that theophylline, one of the
classical agents of bronchodilators, has an anti-
inflammatory effect in some clinical studies for the
long-term management of asthma.3–5 Because of
these observations, treatment with sustained-re-
lease theophylline has been recommended for long-
term medication as a mild anti-inflammatory agent
as well as a mild to moderate bronchodilator.6 On
the other hand, treatment with aminophylline, a
theophylline derivative, for managing exacerba-
tions of asthma is not generally recommended in
some guidelines for asthma management because
no additional benefits to inhaled b2-agonist therapy
were reported in several studies.7,8 On the con-
trary, beneficial findings of aminophylline during
asthma exacerbations are also supported in various
other studies.9,10 In addition to these studies, we
have previously demonstrated that the treatment
with aminophylline is effective for the manage-
ment of asthma exacerbations as well as the
treatment with inhaled b2-agonist.
11 Furthermore,
we have also shown that theophylline could act as
an anti-inflammatory agent with the induction of
apoptosis in activated eosinophils.12 These previous
findings lead us to the hypothesis that aminophyl-
line may act as an anti-inflammatory agent as well
as a bronchodilator even in the treatment of
exacerbations of asthma. In this study, we at-
tempted to clarify if the treatment with aminophyl-
line could suppress the release of some chemical
mediators such as eosinophil cationic protein (ECP).
In this series, we measured PEF, saturation of
oxygen by pulse oxymeter (SpO2) as clinical para-
meters. We also measured these parameters in
the treatment with inhalation of salbutamol, a
b2-agonist, which is generally recommended as a
quick-relief medication.Methods
Subjects
Eighteen adult asthmatic patients (males:females ¼
8:10, average age 47.3, range 22–70 years ), with
mild to moderate acute exacerbations visiting the
outpatient department of our hospital, were takenin this study. Before starting this study, the level of
asthma severity during long-term medication and
severity of exacerbation of each patient were
evaluated by physicians. By these evaluations,
patients with severe symptoms or histories of a
high risk of asthma exacerbations such as a previous
history of life-threatening acute asthma exacerba-
tions, hospitalization within the previous year, a
history of intubations for asthma, and recent
reductions or cessation of glucocorticosteroid
therapy6 were excluded because we treated these
patients with systemic glucocorticosteroids imme-
diately. If patients took oral glucocorticosteroids
before coming to our hospital, such asthmatic
patients were also excluded from this study to
avoid an influence of pharmacological effects of
systemic steroid.
All patients who were informed of the purpose of
the study gave consent to entry before treatment
with aminophylline or salbutamol, and the study
was approved by Teikyo University and the Hospital
Ethics Committee.Study design
Either aminophylline or salbutamol was randomly
selected as an initial treatment for an asthma
attack. Regardless of the choice of initial treat-
ment, we started intravenous infusion into a
patient with maintenance fluid after evaluating
the patient’s condition from a detailed medical
history and by checking the patient’s blood pres-
sure (BP), pulse rate (PR), PEF, SpO2 and theophyl-
line concentration. Those who were selected to
undergo intravenous aminophylline, received the
medication in a dose designed to reach its serum
concentration of theophylline between 15 and
20 mg/ml within an hour. Briefly mentioned about
the methods of aminophylline infusion, dose (mg)
of aminophylline was calculated with Eq. (1),
assuming the distribution volume is 0.45/kg and
aminophylline contains 80% of theophylline as a
target of final concentration of theophylline to
18mg/ml.13
Dose ðmgÞ of aminohylline
¼ ð18 cÞ  0:45=0:8 BW, ð1Þ
where c is the serum concentration of theophylline
at the time of visit to hospital (mg/ml) and BW is
the actual body weight or standard body weight,
whichever is smaller (kg).
If the initial therapy was inhaled b2-agonist, 2mg
of the salbutamol (0.5% solution) was delivered by
nebulizer every 15min for the first hour. Para-
meters of inflammation, serum concentrations of
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nophil cationic protein (ECP), histamine, serotonin,
thromboxane B2 (TXB2), leukotriene C4 (LTC4) were
measured before and one hour after the initial
treatment. The effectiveness of these therapies
were assessed by checking subjective feelings such
as dyspnea, chest tightness, and cough, physical
findings such as wheezes, and difficulty in speaking,
and use of accessory muscles, and physiological
parameters listed above. After the studies, the use
of additional treatment including systemic corti-
costeroids was dependent on the judgment of each
physician (asthma specialist) responsible for treat-
ing the patient.Measurement of serum theophylline
The levels of serum theophylline were measured
using a fluorescence polarization immunoassay
(TDXs, Dianabot Co., Tokyo, Japan).Measurement of serum mediators
The levels of serum ECP were measured with its
release during 1 h incubation via coagulation by
Pharmacia kit (CAP-System ECP FEIA; Amersham
Pharmacia Biotech, Uppsala, Sweden). The levels
of serum concentrations of histamine were mea-
sured with radio immunoassay (RIA) kit (Immuno-
tech Inc., Maine, USA) and serotonin were
measured with high performance liquid chemato-
graphy (HPLC) method, the serum concentrations
of TXB2 were measured with RIA kit (NEN Dupont
Pharmaceuticals Co., Delaware, USA), and the
serum concentrations of LTC4 were measured with
the HPLC-RIA method (TRK905; Amersham Pharma-
cia Biotech).Peak expiratory flow measurement
PEF was measured twice on each occasion with an
Assesss peak flow meter (Healthscan Products Inc.,
New Jersey, USA), and the optimal value was
recorded.Statistical analysis
Data shown in this paper are presented as
mean7SEM and a percentile value for prevalence.
One way ANOVA was used for comparisons among
groups consisting of more than three, and the
paired t-test was employed for analyzing para-
meter changes before and after treatment. A value
of Po0.05 was considered significant for all tests.Results
Summary of human subjects
The characteristics of subjects, who were randomly
divided into two groups according to their initial
treatment either with aminophylline or with
salbutamol, are summarized in Table 1. Severity
of asthma and that of asthma exacerbations of each
patient were classified according to the GINA
guideline.6 There are no significant differences as
to the background of asthma including duration and
severity of asthma and severity of exacerbations
before each initial treatment between these two
groups. Furthermore, in a view of regular therapy,
all patients enrolled in this study were treated with
inhaled cortiocsteroids (beclomethasone diproprio-
nate) and with sustained-release theophylline as a
long-term controller. Doses of inhaled cortiocster-
oids, doses and serum concentrations of theophyl-
line were not different between these two groups.
No patients were treated with oral corticosteroids
as long-term-control medication for asthma in this
study. As another regular therapy, three subjects in
theophylline group received treatment with pran-
lukast (leukotriene antagonist) in a dose of 450mg
and two subjects in salbutamol group received that
agent in a same dose. All patients were successfully
treated with each treatment without systemic
corticosteroids during the period of this study. No
adverse effects such as tremor, headache or nausea
were observed in this series.
Serum theophylline concentration
No significant difference was observed between the
groups of patients treated with aminophylline or
salbutamol in terms of the serum levels of
theophylline (mg/ml) before those treatments
(7.673.5 and 7.572.7, respectively). After ami-
nophylline treatment, patients showed a significant
increase in serum theophylline (16.271.5).
Subjective feelings and physical findings
Treatment with amiophylline improved subjective
feelings such as dyspnea in 80%, chest tightness in
70%, and cough in 90%, and sulbutamol improved
these symptoms of dyspnea in 63%, chest tightness
in 75%, and cough in 88% in our series. Treatment
with amiophylline improved physical findings such
as wheezes in 80%, and difficulty in speaking in
100%, and use of accessory muscles in 90%;
salbutamol improved wheezes in 75%, and difficulty
in speaking in 75%, and use of accessory muscles in
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Table 1 Characteristics of patients.
Aminophylline (n ¼ 10) Salbutamol (n ¼ 8)
Sex, n (%)
Female 6 (60) 4 (50)
Male 4 (40) 4 (50)
Atopy, n (%)
Non-atopics 2 (20) 3 (37.5)
Atopics 8 (80) 5 (62.5)
Age (yr) mean (range) 47.6 (22–62) 46.9 (28–70)
Asthma duration, n (%)
o2 years 2 (20) 2 (25)
2–10 years 3 (30) 2 (25)
410 years 5 (50) 4 (50)
Severity of asthma in long-term, n (%)
Mid Persistent 6 (50) 4 (50)
Moderate Persistent 2 (20) 3 (38)
Severe Persistent 2 (20) 1 (12)
Regular therapy: dose, mean (range)
Inhaled-corticosteroids (BDP (mg)) 630 (400–1600) 660 (400–1200)
Sustain-release theophylline (mg) 330 (200–600) 290 (200–600)
Severity of asthma exacerbations; n (%)
Mild 3 (30) 2 (25)
Moderate 7 (70) 6 (75)
BDP: beclomethasone dipropionate.
Aminophilline suppress the release of medical mediators in treatment of acute asthma 54563%. No significant differences were seen between
the treatment with aminophylline and salbutamol
in these clinical symptoms in the present study.
Values of PEF and SpO2
Significant improvements of PEF (l/min) and SpO2
were observed in both groups. The values of PEF (l/
min) and SpO2 (%) improved from 151.4710.5 to
259.4726.6 (P ¼ 0:008) and from 94.770.5 to
96.670.3 (P ¼ 0:010), respectively, with the treat-
ment with aminophylline (Fig. 1a). The values of
PEF (l/min) and SpO2 (%) improved from
174.3731.1 to 250.0730.4 (P ¼ 0:009) and from
95.470.7 to 98.170.3 (P ¼ 0:046), respectively,
with the treatment with salbutamol (Fig. 1b).
Serum concentration of pro-inflammatory
mediators
Significant decreases of serum concentrations were
observed for ECP (19.372.7 vs. 14.772.1 mg/l,
P ¼ 0:009), histamine (6.572.1 vs. 3.270.7 nM/l,
P ¼ 0:037), and serotonin (126.6713.5 vs.
97.2714.5 ng /ml, P ¼ 0:048) after one hour from
treatment with aminophylline for 1 h (Fig. 2a–c).The trend of decrease in the concentration of TXB2
was also observed by treatment with aminophylline
and the decrease was significant if the percentile
values of concentrations were compared (Table 2).
No significant changes were observed in the con-
centration of LTC4 by the treatment with amino-
phylline. No significant changes of ECP or other
mediators were detected following treatment with
salbutamol in the present study (Fig. 3a–c).
Furthermore, negative correlation between the
increase of theophylline concentration and the
decrease of the ECP level was observed in this
study (Fig. 4). The values of PEF, SpO2, and the
chemical mediators are summarized in Table 2.Discussion
The presence of airway inflammation has been
recognized to play a pivotal role in bronchial
asthma and treatment with anti-inflammatory
agents has recently been recommended as long-
term-control medication. To date, sustained-re-
lease theophylline is recommended as a mild anti-
inflammatory agent as well as a bronchodilator for
long-term medication.3,4 However, treatment with
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Figure 1 Clinical parameters such as PEF (l/min) and SpO2 (%) were significantly improved by the treatment with
infused aminohylline (a) and with inhaled salbutamol (b). *Po0.01 and **Po0.05.
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Figure 2 Serum levels of (a) ECP (mg/l), (b) histamine (nM/l), (c) serotonin (ng/ml) were significantly decreased by
infused aminophylline. *Po0.01 and **Po0.05.
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Table 2 Changed values of clinical parameters and chemical mediators before and after treatment with
aminophylline or salbutamol.
Before After % Value (P-value)
Aminophylline
Theophylline conc. 7.673.5 16.271.5 242.4768.7 (0.008)
PEF 151.4710.5 259.4726.6 172.4719.3 (0.008)
SpO2 94.770.5 96.670.3 102.070.4 (0.010)
ECP 19.372.7 14.772.1 76.575.5 (0.009)
Histamine 6.572.1 3.270.7 64.978.3 (0.037)
TXB2 18.774.0 14.373.0 78.378.8 (0.048)
LTC4 45.574.1 42.974.2 95.572.9 (0.108)
Serotorin 126.6713.5 97.2714.5 76.9710.5 (0.680)
Salbutamol
Theophylline conc. 7.572.7 7.271.3 94.771.9 (0.980)
PEF 174.3731.1 250.0730.4 154.8713.0 (0.009)
SpO2 95.470.7 98.170.3 102.970.9 (0.046)
ECP 16.573.8 17.874.0 116.1741.9 (0.811)
Histamine 4.470.7 4.970.7 131.6730.6 (0.675)
TXB2 27.4710.6 23.479.1 92.8723.9 (0.080)
LTC 40.070.1 39.870.4 99.573.5 (0.998)
Serotonin 118.4720.7 118.6723.7 97.674.0 (0.656)
Theophylline conc: serum theophylline concentration (mg/ml), PEF: peak expiratory flow rate (l/min), SpO2: saturation of
oxygen by pulse oxymeter (%), ECP: eosinophil cationic protein (mg/l), TXB2: thromboxane B2 (pg/ml), LTC4: leukotriene C4 (pg/
ml). Histamine is measured in unit of nM/l and serotonin in unit ng/ml. % Value is changed value of each parameter after
treatment as compared to those of before and P-value of before vs after in each treatment is presented in parenthesis. Each
value is presented as mean7SEM.
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Figure 3 No significant changes were demonstrated in the serum levels of (a) ECP, (b) histamine, (c) serotonin by the
treatment with inhaled salbutamol.
Aminophilline suppress the release of medical mediators in treatment of acute asthma 547aminophylline for managing exacerbations of asth-
ma is still to be discussed.
In this study, we attempted to clarify whether
intravenous aminophylline is beneficial in the
treatment for asthma exacerbations in adults
accompanied with its anti-inflammatory effects.
To verify this question, we designed the study to
measure the pro-inflammatory mediators which
might reflect the inflammatory processes during
asthma exacerbations before and after the treat-
ment with aminophylline or salbutamol. Due to theincreased expressions of ECP, histamine, serotonin,
TXB2 which is a metabolite of TXA2, and LTC4 during
asthma exacerbations or in symptomatic asth-
matics14–17 the effect of aminophylline on these
mediators was studied. We also measured PEF and
SpO2 as clinical markers. In the present study it was
revealed that clinical findings such as PEF and SpO2
were significantly improved to the same extent in
both treatments with aminophylline and salbuta-
mol. Treatment with aminophylline increased ser-
um theophylline concentrations above those seen
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Figure 4 Negative correlations between the increase of
theophylline concentrations and the decrease of the ECP
levels (Po0.05) were observed.
J. Nakano et al.548with sustained release theophylline reaching levels
associated with maximal bronchodilator effects
(15–20 mg/ml).
The serum concentrations of ECP, histamine, and
serotonin or the percentile value of TXB2 were
significantly decreased by treatment with amino-
phylline although no significant changes were
detected in the treatment with salbutamol. In in
vitro studies theophylline has been demonstrated
to stabilize or inactivate a variety of inflammatory
cells including mast cells,18 basophils,19 neutro-
phils, macrophages20 and platelets.21 In addition to
these findings, we have previously reported that
theophylline induced apoptosis in eosinophils which
were activated and prolonged their survival by IL-
5.12 In this study, aminophylline had no effect on
cell counts including levels of eosinophils; however,
negative correlation between the increase of
theophylline concentration and the decrease of
the ECP level was noticed in this study (Fig. 4).
These findings might support another anti-inflam-
matory effect of theophylline on eosinophil activa-
tion without its cell numbers. Collectively, we
speculate that the treatment with aminophylline is
effective in attenuating asthma exacerbations not
only by bronchodilation but also by its inhibitory
effects on pro-inflammatory mediator release from
inflammatory cells, which were observed in various
in vitro studies12,18–21 or in the present study.
In some in vivo studies, a b2-agonist was
described to have an anti-inflammatory effect by
suppressing the eosinophil activation or mast cell
mediator release.22,23 However no significant
changes of levels of the chemical mediators weredetected in the present study. We speculate that
serum concentration of b2-agonist achieved with
the treatment of inhaling this agent was adequate
for bronchodilatation but was too low to induce its
anti-inflammatory effect in general use for acute
asthma.24 Furthermore, it has been demonstrated
that a short-acting b2-agonist such as salbutamol
does not inhibit the ECP release from activated
eosinophils, which was observed with long-acting
b2-agonist such as salmeterol,
25,26 or some studies
reported that the anti-inflammatory effects of
salbutamol are only apparent in vitro and do not
occur in vivo.27 These findings are consistent with
our results in which the treatment with inhaled
short-acting b2-agonist failed to inhibit any med-
iator release during asthma exacerbations despite
the significant improvement of airflow limitation.
In the recent guidelines for asthma management,
treatment with inhaled short-acting b2-agonist and
systemic corticosteroid is recommended as the
initial treatment for asthma exacerbations;
furthermore, treatment with aminophylline is
considered in the management of severe asthma
exacerbations.6 Indeed, it has been demonstrated
that treatment with aminophylline added to treat-
ments with inhaled short-acting b2-agonist and
systemic corticosteroids is useful to reduce fre-
quent nebulizations of b2-agonist.
28 Similarly, in-
fused aminophylline adding to other treatments
with short-acting b2-agonist, methylprednisolome,
and inhaled ipratropium has been revealed to
improve clinical asthma conditions.29–31 Since air-
way inflammation is critical not only in the chronic
phase of asthma but also in acute exacerbations,
we consider that the appropriate use of aminophyl-
line will be beneficial for asthma exacerbations due
to its bronchodilatation and its inhibitory effect on
the releases of chemical mediators as demon-
strated in this study.
To evaluate an anti-inflammatory effect of
aminophylline, we excluded patients with severe
symptoms or histories of a high risk of asthma
exacerbations in this study to avoid an effect of
systemic steroid, because these asthmatics are
recommended to be treated with medications
including glucocorticosteroid as severe asthma
attacks in the recent guideline.6 We realized that
this might be a limitation of our study and further
research is necessary to investigate if aminophyl-
line could act as an anti-inflammatory agents
combined with systemic glucocorticosteroid. How-
ever, in some cases of asthma exacerbations,
treatments with systemic glucocorticosteroids are
difficult for some complications,32,33 and combined
treatments with aminophylline added to systemic
corticosteroids are useful in other studies.27,34
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prednisone had various anti-inflammatory effects
but could not inhibit the release of thromboxane in
airways.35 We think treatment with aminophylline
is still useful in these situations. Moreover, in our
previous study we revealed that amionphylline
significantly reduced further treatments as com-
pared to salbutamol at the time point of one hour
after the initial treatments, which is the same time
point of this study, although improvement of
clinical parameters such as PEF and physical
findings such as wheezes are not different between
these two treatments.11 These findings could
reflect an effect of theophylline as an anti-
inflammatory agent with improving airflow limita-
tion of small airway by measuring V5036 although
these parameters were not quantified in the
present study. We also speculated that the findings
of our previous study might reflect some anti-
inflammatory effects of amiophylline which lead to
reduce additional treatment after one hour from
the initial point of the study as compared to
salbutamol.
In conclusion, appropriate use of infused amino-
phylline could be as beneficial as inhaled salbuta-
mol by the nebulizer for acute exacerbations of
asthma. Moreover, the inhibitory effects of amino-
phylline on the release of pro-inflammatory med-
iators may contribute to the treatment for acute
asthma exacerbations.Acknowledgments
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